POEVOLUS DESIGNED TO COMPETE Other AEs of Interest • Ptosis (drug-related) • Eyebrow - Jeuveau 0%, Botox 0.4% 10 2 Days 14 Days 30 Days 90 Days 120 Days 150 Days Jeuveau® Botox® 54.5 95.7 95.3 76.7 57.8 37.9 57.4 95.1 93.9 73.9 51.5 34.3 11 Millennials "ORIGINAL" • 20U Jeuveau® Jeuveau® | --- | --- | --- | --- | --- | |-------------------------------------|-------------------------------------------|-----------------------|--------------------|----------------------| | ADVERSE EVENTS | Adverse Event Summary ...

Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants David Erickson - Vice President of Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Officer and Head of Research and Development Sandra Beaver - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Inc. Marc Goodman - SVB Securities Douglas Tsao - H.C. Wainwright & Co. Louise Chen - Cantor Fitzgerald & Co. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________ FORM 10-K _____________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) Delaware 46-1385614 (I.R.S. Employer Identification Number) 520 Newport Center Dr. ...

This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product; the potential market acceptance, demand market size, adoption rate, revenue exp ...

Evolus, Inc. (NASDAQ:EOLS) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Erickson – Vice President-Investor Relations David Moatazedi – President and Chief Executive Officer Sandra Beaver – Chief Financial Officer Conference Call Participants Marc Goodman – SVB Securities Carvey Leung – Cantor Fitzgerald Annabel Samimy – Stifel Douglas Tsao – H.C. Wainwright Operator Greetings, and welcome to the Evolus Third Quarter 2022 Earnings Conference Call. At this time all p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

Evolus, Inc. (NASDAQ:EOLS) Q2 2022 Earnings Conference Call August 1, 2022 9:00 AM ET Company Participants David Erickson - Vice President, Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Officer and Head of Research and Development Conference Call Participants Louise Chen - Cantor Fitzgerald Annabel Samimy - Stifel Marc Goodman - SVB Greg Fraser - Truist Securities Serge Belanger - Needham and Company Douglas Tsao - H.C. Wainwright Uy Ear - Mizuho Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

gg evolus™ M A Y 202 2 Investor Presentation | --- | --- | --- | |-------|-------------------|-------| | | | | | | | | | | | | | | 8 | | | | | | | | our Purpose | | | | To make the her | | | | beauty experience | | | | delightful and | | | | achievable | | Disclosures Special Note Regarding Forward-Looking Statements This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained i ...

Evolus, Inc. (NASDAQ:EOLS) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants David Erickson - Vice President-Investor Relations David Moatazedi - President and Chief Executive Officer Lauren Silvernail - Chief Financial Officer and Executive Vice President, Corporate Development Conference Call Participants Marc Goodman - SVB Leerink Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Evolus First Quarter 2022 Earnings Call. At this time, our participants are in ...